Skip to main content
SpringerLink
Log in

Surgical Options in Undifferentiated Thyroid Carcinoma

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Undifferentiated or anaplastic carcinoma is an uncommon histologic type of thyroid cancer. It is one of the most aggressive malignancies associated with a poor prognosis. Most patients are elderly presenting as locally advanced disease with nodal and distant metastases. Complete surgical resection is frequently not possible and there is no effective systemic therapy. Aggressive multimodal therapy including surgery, radiation, and chemotherapy is recommended for management. However, because of the rarity of the disease, its aggressiveness and the lack of prospective treatment protocols, nearly all evidence in the literature comes from retrospective case series or cohort studies for selected patients’ subgroups treated over a relatively long study period. Evidence of therapeutic benefit of one treatment option over another is lacking. Prognosis remains dismal with a median survival of 2–12 months Surgery remains an important component of the multimodal therapy and is commonly adopted as primary treatment. Although radical resection should be discouraged, resection without inducing significant morbidity can be considered for good risk patients with resectable tumors. It provides an effective form of palliation with potential cure when combined with postoperative radiotherapy and/or chemotherapy. Patients selected for surgical resection was frequently identified to have improved survival. A regime of preoperative hyperfractionated radiotherapy and doxorubicin followed by surgery when feasible has been documented to achieve local control and avoid tracheostomy for ATC patients. Because of the ineffectiveness of all conventional treatment modalities, novel molecular targeted therapies are being developed to tackling this uniformly fatal disease with promising results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004;11(12):1093–1097

    Article  PubMed  Google Scholar 

  2. Reynolds RM, Weir J, Stockton DL, et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 2005;62:156–162

    Article  Google Scholar 

  3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–2167

    Article  CAS  PubMed  Google Scholar 

  4. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119–128

    PubMed  Google Scholar 

  5. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453–464

    Article  PubMed  Google Scholar 

  6. Ain KB. Anaplastic thyroid carcinoma: behaviour, biology, and therapeutic approaches. Thyroid 1998;8:715–716

    Article  CAS  PubMed  Google Scholar 

  7. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16:64–69

    Article  CAS  PubMed  Google Scholar 

  8. Rosai J, Saxen EA, Woolner L. Undifferentiated and poorly differentiated carcinoma. Semin Diagn Pathol 1985:2;123–136

    Google Scholar 

  9. Auersperg M, Us-Krasovec M, Petric G, et al. Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 1990;102:267–270

    CAS  PubMed  Google Scholar 

  10. Venkatesh S, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990;66:321–330

    Article  CAS  PubMed  Google Scholar 

  11. Schlumberger M, Parmentier C, Delisle MJ, et al. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564–566

    Article  CAS  PubMed  Google Scholar 

  12. Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3–9

    Article  CAS  PubMed  Google Scholar 

  13. DeMeter JG, De Jong SA, Lawrence AM, et al. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 2001;110:956–961

    Google Scholar 

  14. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:83–88

    CAS  PubMed  Google Scholar 

  15. Hadar T, Mor C, Shvero J, et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993;19:511–516

    CAS  PubMed  Google Scholar 

  16. Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993;26:125–128

    CAS  PubMed  Google Scholar 

  17. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348–1354

    Article  CAS  PubMed  Google Scholar 

  18. Biganzoli L, Gebbia V, Maiorino L, et al. Thyroid cancer: different outcomes to chemotherapy according to tumour histology. Eur J Cancer 1995;31:2423–2424

    Article  Google Scholar 

  19. Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995:17:71–77

    Article  Google Scholar 

  20. Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36–41

    Article  CAS  PubMed  Google Scholar 

  21. Nilsson O, Lindeberg J, Zedenius J, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998;22:725–730

    Article  CAS  PubMed  Google Scholar 

  22. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of thyroid. Am J Surg 1999;177:337–339

    Article  CAS  PubMed  Google Scholar 

  23. Passler C, Scheuba C, Prager G, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC): a retrospective analysis. Langenbeck’s Arch Surg 1999:384:284–293

    Article  CAS  Google Scholar 

  24. Voutilainen PE, Multanen M, Haapiainen RK, et al. Anaplastic thyroid carcinoma survival. World J Surg 1999;23:975–979

    Article  CAS  PubMed  Google Scholar 

  25. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587–94

    Article  CAS  PubMed  Google Scholar 

  26. Lam KY, Lo CY, Chan KW, et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 2000;231:329–38

    Article  CAS  PubMed  Google Scholar 

  27. Rodriguez JM, Pinero A, Ortiz S, et al. Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg 2000;166:34–38

    CAS  PubMed  Google Scholar 

  28. Busnardo B, Daniele O, Pelizzo MR, et al. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 2000;23:755–761

    CAS  PubMed  Google Scholar 

  29. Haigh PI, Ituarte PHG, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335–2342

    Article  CAS  PubMed  Google Scholar 

  30. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001:130:1028–1034

    Article  CAS  PubMed  Google Scholar 

  31. Besic N, Auersperg M, Us-Krasovec M, et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001:27:260–264

    Article  CAS  PubMed  Google Scholar 

  32. Sugitani I, Kasai N, Fujimoto Y, et al. Prognostic factors and therapeutic strategy for naplastic carcinoma of the thyroid. World J Surg 2001;25:617–622

    Article  CAS  PubMed  Google Scholar 

  33. Pierie JP, Muzikansky A, Gaz RD, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57–62

    Article  PubMed  Google Scholar 

  34. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractiontated radiotherapy and surgery. Br J Cancer 2002;86:1848–1853

    Article  CAS  PubMed  Google Scholar 

  35. Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245–248

    Article  PubMed  Google Scholar 

  36. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractiontated accelerated external radiotherapy. Int J Radiation Oncology Biol Phys 2004;60:1137–1143

    Google Scholar 

  37. Kihara M, Miyauchi A, Yamauchi A, et al. Prognostic factors in anaplastic thyroid carcinoma. Surg Today 2004;34:394–398

    Article  PubMed  Google Scholar 

  38. Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 2004;74:559–562

    Article  PubMed  Google Scholar 

  39. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma: treatment outcomes and prognostic factors. Cancer 2005;103:1330–1335

    Article  PubMed  Google Scholar 

  40. Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based study. Clin Oncol (R Coll Radiol) 2005;17:75–78

    CAS  Google Scholar 

  41. Besic N, Hocevar M, Zgajnar J, et al. Prognostic factors in anaplastic carcinoma of the thyroid — a multivariate analysis of 188 patients. Langenbecks Arch Surg 2005;390:203–208

    Article  PubMed  Google Scholar 

  42. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95S:2–4

    Google Scholar 

  43. Heinrich S, Schäfer M, Rousson V, et al. Evidence-based treatment of acute pancreatitis. A look at established paradigms. Ann Surg 2006;243:154–168

    Article  PubMed  Google Scholar 

  44. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook: TNM classification of malignant tumors, Sixth Edition. New York: Springer-Verlag, 2002

    Google Scholar 

  45. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202–220

    Google Scholar 

  46. Hermann M, Kober F, Hollinsky C, et al. Reinterventions in anaplastic cancers and sarcomas of the thyroid gland. Wien Klin Wochenshr 1990;102:260–264

    CAS  Google Scholar 

  47. Holting T, Meybier H, Buhr H. Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr 1990;102:264–266

    CAS  PubMed  Google Scholar 

  48. Hunt JL, Tometsko M, LiVolsi VA, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003;27:1559–564

    Article  PubMed  Google Scholar 

  49. Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997;14:729–740

    Article  CAS  PubMed  Google Scholar 

  50. Fagin JA, Tang SH, Zeki K, et al. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 1996;56;765–771

    CAS  PubMed  Google Scholar 

  51. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cells. J Clin Endocrinol Metab 1998;83:2516–2522

    Article  CAS  PubMed  Google Scholar 

  52. Nagayama Y, Yokoi H, Takeda K, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000;85:4081–4086

    Article  CAS  PubMed  Google Scholar 

  53. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/C1P1. Oncogene 2006;25:2034–2017

    Article  Google Scholar 

  54. Smit JW, Shroder-van der Elst JP, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000;10:939–943

    Article  CAS  PubMed  Google Scholar 

  55. She M, Yeung SCJ. Combining a matrix metalloproteinase inhibitor, a farnseyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model. Cancer Letters 2006;238:197–201

    Article  CAS  PubMed  Google Scholar 

  56. Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE 788. Mol Cancer Ther 2006;4:632–640

    Article  Google Scholar 

  57. Shi Y, Zou M, Collison K, et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006;91:2373–2379

    Article  CAS  PubMed  Google Scholar 

  58. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Research 2004;10:8594–8602

    Article  CAS  Google Scholar 

  59. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178–2189

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrine Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, SAR, China

    Brian Hung-Hin Lang MS (HK) & Chung-Yau Lo MS (HK)

Authors
  1. Brian Hung-Hin Lang MS (HK)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chung-Yau Lo MS (HK)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chung-Yau Lo MS (HK).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lang, B.HH., Lo, CY. Surgical Options in Undifferentiated Thyroid Carcinoma. World J Surg 31, 969–977 (2007). https://doi.org/10.1007/s00268-007-0776-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-007-0776-7

Keywords

Search

Navigation